Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
4 x# L3 @; c! U% u; ? P1 t! w) U9 B# T( r' F
6 o2 k. L$ Y1 |" o+ o" M/ _2 d% A: M. P H8 K4 V/ R! g2 k7 x" I
Sub-category:% ]+ S. w9 h* s# |2 u3 `2 l
Molecular Targets * A& ~- c3 [2 w) c; Y+ b, U: S
" N3 K- f I: A
& n. z7 |' I) n$ x$ j: b; i6 C
Category:
/ m f9 I# I2 h, _4 t4 ETumor Biology 0 ]- F# r7 s; f
) T" M$ x0 H% A# E" B; ]
0 Q4 n8 f$ g7 W, z* nMeeting:) z F, |# l; W* n- I: N
2011 ASCO Annual Meeting ; h# \$ V/ t+ ~" z
# J l+ k1 T2 h+ C; C
7 L- g- _$ \3 D* FSession Type and Session Title:+ D( Q: f [5 G9 O7 f
Poster Discussion Session, Tumor Biology
4 a4 ]1 J& _2 d$ Q% e. `$ ?
( k2 X8 u& f5 Q/ r8 Y3 }5 s3 w2 S/ V. o
Abstract No:* Y* N7 S) S: `8 S$ t7 `5 J
10517
. k4 S" v" `/ |5 D3 t: z& J0 M5 s5 K+ x4 }
! S X9 r4 O$ c5 ~/ u3 M5 E4 pCitation:, o6 B+ H: Y8 z) _! J
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) ]3 ^6 r( q( L \( e( ]4 t4 X n% X1 O3 K7 c2 b+ N
% N# b% b& m! m$ BAuthor(s):5 S) i1 @! a- f( j, e* r2 I' d/ r
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
$ j& h& s: E j8 w1 j7 U0 Y
5 R! P) m* e3 H: J- p
' U1 U" }5 J; L
" I- g. T b: N' i- d* @' S) aAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
: B0 D- x6 V( ^8 _5 @
. u+ ^' ^; \4 |% r; e4 ZAbstract Disclosures
* E* D4 W0 R N& O: g) } \) w0 A. L, X L( X' U9 K- f" j f. n k
Abstract:! V1 X! \ O4 B6 E0 \
- d0 K2 \4 G5 W% {9 p+ T/ c7 `' c
; ]" E. K, v# B# Z* B) ?- [Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- ?+ @! }9 O/ k& B. J/ C2 i% \3 w
' Q+ ^. _$ e& z6 R z2 h& ^% {. D9 X' s0 j
|
2 V, Q% J5 L# y3 X. }* `
显身卡
